In an agreement with the survival outcomes, FGL2 expression was associated with several favourable risk factors for GIST recurrence, such as a low cell proliferation rate, small size and the absence of tumour necrosis, and also with low TIL counts. This evidence concerns the gene FGL2 and gastrointestinal stromal tumor.